IVVD vs ZBIO
IVVD: Invivyd develops monoclonal antibody therapeutics for serious viral infections, with PEMGARDA approved for COVID-19 emergency use and a pipeline targeting RSV, measles, and other evolving pathogens. ZBIO: Zenas BioPharma is a clinical-stage immunology company developing obexelimab, a novel bifunctional B cell-inhibiting monoclonal antibody, and orelabrutinib, a CNS-penetrant BTK inhibitor, for multiple high-value autoimmune disease indications.
Side-by-side fundamentals
| Metric | IVVD | ZBIO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $0.62 | $31.49 | |
| Market cap as of 2026-07-23 | $183M | $2.0B | |
| PEG as of 2026-07-23 | n/a | -0.10 | |
| Net margin as of 2026-07-23 | -138.9% | -3777.4% | IVVD higher |
| Gross margin as of 2026-07-23 | +92.9% | n/a | |
| Operating margin as of 2026-07-23 | -146.4% | -3830.6% | IVVD higher |
| ROE as of 2026-07-23 | -53.5% | -167.7% | IVVD higher |
| ROA as of 2026-07-23 | -41.6% | -97.4% | IVVD higher |
| Debt / equity as of 2026-07-23 | 0.00 | 1.04 | IVVD lower |
| Revenue growth (YoY) as of 2026-07-23 | +52.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | n/a | -55.3% | |
| Beta as of 2026-07-23 | 0.75 | 0.70 | |
| 1-year return as of 2026-07-22 close | -11.5% | +126.5% | ZBIO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.